Cardiff Oncology (CRDF) Stock Analysis & AI Equity Report
Cardiff Oncology (CRDF) overview
Cardiff Oncology (CRDF) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 0.6m and operating profit of USD -49.0m; the year-end share price was 2.81 USD and market capitalisation was USD 192m. Cardiff Oncology is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Cardiff Oncology's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Cardiff Oncology
Cardiff Oncology is a clinical-stage biotechnology company developing cancer therapies based on PLK1 inhibition. Its lead drug candidate, onvansertib, is an oral, selective PLK1 inhibitor being studied in combination with standard cancer treatments. Clinical programs include trials in RAS-mutated metastatic colorectal cancer and investigator-led studies in pancreatic cancer, small cell lung cancer, triple-negative breast cancer and chronic myelomonocytic leukemia.
Generate the Cardiff Oncology report
Cardiff Oncology is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Cardiff Oncology and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Cardiff Oncology
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.